The DOI matches its Crossref record; 12 of the 12 references it cites were found in a registry or an index.
Phosphodiesterase Type 5 as a Target for the Treatment of Hypoxia-Induced Pulmonary Hypertension
Abstract
Background— Phosphodiesterase type 5 (PDE5) is a novel therapeutic target for the treatment of pulmonary hypertension. This study examined the distribution of PDE5 in normal and hypoxic lung and the effect of chronic PDE5 inhibition with sildenafil, initiated before and during exposure to hypoxia, on pulmonary artery pressure (PAP) and structure. Methods and Results— Sprague-Dawley rats were exposed to hypoxia (10% O 2 ) for up to 42 days. PAP, measured continuously by telemetry, increased gradually by 20 to 40 mm Hg, reaching a plateau between 10 and 14 days, and declined to normal levels on return to normoxia. PDE5 immunoreactivity was localized to smooth muscle cells in the medial layer of pulmonary arteries and veins in the normal lung and in distal muscularized arteries (<25 μm diameter) after hypoxia-induced pulmonary hypertension. Sildenafil (25 or 75 mg · kg −1 · d −1 ) given before hypoxia produced marked dose-dependent inhibition in the rise of PAP (60% to 90% reduction; P <0.0001) and vascular muscularization (28.4±5.0% reduction; P <0.001). When begun after 14 days of hypoxia, sildenafil significantly reduced PAP (30% reduction; P <0.0001) and partially reversed pulmonary artery muscularization (39.9±4.9% reduction; P <0.001). Conclusions— PDE5 is found throughout the muscularized pulmonary vascular tree, including in newly muscularized distal pulmonary arteries exposed to hypoxia. PDE5 inhibition attenuates the rise in PAP and vascular remodeling when given before chronic exposure to hypoxia and when administered as a treatment during ongoing hypoxia-induced pulmonary hypertension.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Barst, R. J., Rubin, L. J., Long, W. A., McGoon, M. D., Rich, S., Badesch, D. B., Groves, B. M., Tapson, V. F., Bourge, R. C., Brundage, B. H., et al. (1996) · New England Journal of Medicine · doi:10.1056/nejm199602013340504 · Cited by 2,698
Antigen unmasking on formalin‐fixed, paraffin‐embedded tissue sections
Cattoretti, G., Pileri, S., Parravicini, C., Becker, M. H. G., Poggi, S., Bifulco, C., Key, G., D'Amato, L., Sabattini, E., Feudale, E., et al. (1993) · The Journal of Pathology · doi:10.1002/path.1711710205 · Cited by 721
Michelakis, E., Tymchak, W., Lien, D., Webster, L., Hashimoto, K., & Archer, S. (2002) · Circulation · doi:10.1161/01.cir.0000016641.12984.dc · Cited by 577
Sildenafil Inhibits Hypoxia-Induced Pulmonary Hypertension
Zhao, L., Mason, N. A., Morrell, N. W., Kojonazarov, B., Sadykov, A., Maripov, A., Mirrakhimov, M. M., Aldashev, A., & Wilkins, M. R. (2001) · Circulation · doi:10.1161/hc2901.093117 · Cited by 488
Self-citationPharmacokinetics and metabolism of sildenafil in mouse, rat, rabbit, dog and man
WALKER, D. K. (1999) · Xenobiotica · doi:10.1080/004982599238687 · Cited by 401
Effects of sildenafil citrate on human hemodynamics
Jackson, G., Benjamin, N., Jackson, N., & Allen, M. J. (1999) · The American Journal of Cardiology · doi:10.1016/s0002-9149(99)00043-0 · Cited by 368
Molecular cloning and characterization of a distinct human phosphodiesterase gene family: PDE11A
Fawcett, L., Baxendale, R., Stacey, P., McGrouther, C., Harrow, I., Soderling, S., Hetman, J., Beavo, J. A., & Phillips, S. C. (2000) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.97.7.3702 · Cited by 359
Self-citationCharacterization of a purified bovine lung cGMP-binding cGMP phosphodiesterase.
Thomas, M. K., Francis, S. H., & Corbin, J. D. (1990) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(18)77210-4 · Cited by 226
Regulation of cGMP-specific Phosphodiesterase (PDE5) Phosphorylation in Smooth Muscle Cells
Rybalkin, S. D., Rybalkina, I. G., Feil, R., Hofmann, F., & Beavo, J. A. (2002) · Journal of Biological Chemistry · doi:10.1074/jbc.m106562200 · Cited by 218
Nakaura, H., Morimoto, S., Yanaga, F., Nakata, M., Nishi, H., Imaizumi, T., & Ohtsuki, I. (1999) · American Journal of Physiology-Cell Physiology · doi:10.1152/ajpcell.1999.277.2.c225 · Cited by 69
Cited by
Lugnier, C. (2006) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2005.07.003 · Cited by 870
Pulmonary Arterial Hypertension
McLaughlin, V. V., & McGoon, M. D. (2006) · Circulation · doi:10.1161/circulationaha.104.503540 · Cited by 664
Sildenafil: from angina to erectile dysfunction to pulmonary hypertension and beyond
Ghofrani, H. A., Osterloh, I. H., & Grimminger, F. (2006) · Nature Reviews Drug Discovery · doi:10.1038/nrd2030 · Cited by 629
Sildenafil versus Endothelin Receptor Antagonist for Pulmonary Hypertension (SERAPH) Study
Wilkins, M. R., Paul, G. A., Strange, J. W., Tunariu, N., Gin-Sing, W., Banya, W. A., Westwood, M. A., Stefanidis, A., Ng, L. L., Pennell, D. J., et al. (2005) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.200410-1411oc · Cited by 380
Self-citationAntiproliferative Effects of Phosphodiesterase Type 5 Inhibition in Human Pulmonary Artery Cells
Wharton, J., Strange, J. W., Møller, G. M. O., Growcott, E. J., Ren, X., Franklyn, A. P., Phillips, S. C., & Wilkins, M. R. (2005) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.200411-1587oc · Cited by 371
Self-citation
Metadata
- Authors
- Sebkhi, A., Strange, J. W., Phillips, S. C., Wharton, J., & Wilkins, M. R.
- Venue
- Circulation
- Published
- 2003-07
- Volume
- 107
- Issue
- 25
- Pages
- 3230-3235
- ISSN
- 0009-7322 (ISSN-L)
- 1524-4539
- OpenAlex
- W1989792368
- Cited by
- 261
- References
- 12
- FWCI
- 18.26
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Phosphodiesterase Type 5 as a Target for the Treatment of Hypoxia-Induced Pulmonary Hypertension. https://app.cochat.ai/papers/10.1161/01.cir.0000074226.20466.b1
- The paper
- Sebkhi, A., Strange, J. W., Phillips, S. C., Wharton, J., & Wilkins, M. R. (2003). Phosphodiesterase Type 5 as a Target for the Treatment of Hypoxia-Induced Pulmonary Hypertension. Circulation. https://doi.org/10.1161/01.cir.0000074226.20466.b1
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.